RankingsPricing
  1. US-listed companies
  2. NEUROCRINE BIOSCIENCES INC
  3. Financials
  4. Stockholders' equity

NEUROCRINE BIOSCIENCES INCNBIX

Market cap
$15.3B
P/E ratio
SummaryFinancials
Period EndStockholders' equity (Million USD)YoY (%)
Dec 31, 20242,590+16.03%
Dec 31, 20232,232+30.69%
Dec 31, 20221,708+24.29%
Dec 31, 20211,374+22.00%
Dec 31, 20201,126+76.82%
Dec 31, 2019637+32.48%
Dec 31, 2018481+29.19%
Dec 31, 2017372+18.19%
Dec 31, 2016315-25.82%
Dec 31, 2015424+103.38%
Dec 31, 2014209+73.32%
Dec 31, 2013120-22.00%
Dec 31, 2012154+156.94%
Dec 31, 201160

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)